Sort
4,870 grants matching “glp 1”
Neuroprotective role of GLP-1 receptor agonists
$765,761Nigel H. Greig · National Institute On Aging · ZIA · FY2019 · AG
Pathogenesis of youth onset pre-diabetes and Type 2 diabetes
$764,043Sonia Caprio · Yale University · R01 · FY2023 · DK
Development of PEGylated MTI-101 for the treatment of relapsed Myeloma
$763,695Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2019 · CA
Nitrite dependent protection against Cl2 gas toxicity_role of chlorinated lipids
$763,659Rakesh Pravinchandra Patel · University Of Alabama At Birmingham · U01 · FY2014 · ES
Novel SCD1 inhibitors for treatment of cancer
$763,181John A Copland · Modulation Therapeutics, Inc. · R42 · FY2018 · CA
Biobehavioral Studies of Obesity, Weight loss and Recidivism
$762,621Ranganath Muniyappa · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
Long-acting Antiviral Treatment for HBV
$762,072Rodney J.y. Ho · University Of Washington · R01 · FY2024 · AI
Cocaine Addition and the Need-State Hypothesis
$762,063Patricia Sue Grigson · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2025 · DA
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy
$760,561Grace A McComsey · Case Western Reserve University · R01 · FY2022 · DK
Molecular Antecedents of Miscarriage
$760,527Raina N Fichorova · Brigham And Women'S Hospital · R01 · FY2022 · HD
Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons
$760,245Robert Mehalso · Sensodx Ii, Llc · R42 · FY2019 · DA
Bactericidal Intravascular Biosensor for Continuous Reading of Lactate in the lCU Ph2
$760,088Hao Chen · Biocrede, Inc. · R44 · FY2018 · GM
Countermeasures Against Chemical Threats: Countermeasures Against Cyanide
$759,391Steven E Patterson · University Of Minnesota · U01 · FY2011 · NS
Hydrogen Sulfide and GLP-1 Combination Therapy to Treat HFpEF
$759,206David Joseph Lefer · Cedars-Sinai Medical Center · R01 · FY2025 · HL
Evaluation of a Robotic Assisted Surgical System for Hearing Loss
$758,945Allan Henslee · Iotamotion, Inc. · R44 · FY2018 · DC
Saracatinib and 1400W Counteract Nerve Agents-Induced Long-Term Neurotoxicity
$758,641Thimmasettappa Thippeswamy · Iowa State University · U01 · FY2023 · NS
Saracatinib and 1400W Counteract Nerve Agents-Induced Long-Term Neurotoxicity
$758,516Thimmasettappa Thippeswamy · Iowa State University · U01 · FY2025 · NS
PRECLINICAL DEVELOPMENT OF NOVEL SMOKING CESSATION PHARMACOTHERAPIES
$757,870Nurulain T Zaveri · Astraea Therapeutics, Llc · R44 · FY2014 · DA
Countermeasures Against Chemical Threats: Countermeasures Against Cyanide
$757,455Steven E Patterson · University Of Minnesota · U01 · FY2012 · NS
Saracatinib and 1400W Counteract Nerve Agents-Induced Long-Term Neurotoxicity
$756,847Thimmasettappa Thippeswamy · Iowa State University · U01 · FY2024 · NS
Extending inferences of efficacy and selection of transformative diabetes therapies to diverse populations
$756,480Sridharan Raghavan · University Of Colorado Denver · R01 · FY2025 · DK
Real-world utilization, effectiveness, and safety of GLP-1 receptor agonists for alcohol use disorder
$755,539Joshua David Wallach · Emory University · R01 · FY2025 · AA
Targeting superbugs: discovery and development of new broad-spectrum lipopeptides
$755,045Jian Li · Monash University · R01 · FY2013 · AI
Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatm
$753,417Yvonne J Rosenberg · Plantvax, Inc. · R44 · FY2013 · NS
Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent
$752,754Stephen B Kahl · Manzanita Pharmaceuticals, Inc. · R44 · FY2018 · CA